MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Regeneron Pharmaceuticals Inc

Отворен

СекторЗдравеопазване

594.44 0.2

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

583.66

Максимум

599.49

Ключови измерители

By Trading Economics

Приходи

-423M

918M

Продажби

69M

3.8B

P/E

Средно за сектора

14.641

57.333

EPS

12.07

Дивидентна доходност

0.63

Марж на печалбата

24.219

Служители

15,106

EBITDA

-534M

1.1B

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+47.02% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

0.63%

2.63%

Следващи печалби

29.04.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-13B

62B

Предишно отваряне

594.24

Предишно затваряне

594.44

Техническа оценка

By Trading Central

Увереност

Very Strong Bullish Evidence

Regeneron Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

4.02.2025 г., 12:13 ч. UTC

Печалби

Regeneron 4Q Revenue Up on Strong Sales of EYLEA HD

22.04.2025 г., 10:51 ч. UTC

Топ новини

Drug Companies Step Up 'Make in America' Plans to Counter Tariffs -- WSJ

28.02.2025 г., 12:00 ч. UTC

Топ новини

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

4.02.2025 г., 11:58 ч. UTC

Печалби

Regeneron 4Q Rev Up on Strong Sales of EYLEA HD

4.02.2025 г., 11:37 ч. UTC

Печалби

Regeneron Pharma Sees 2025 Adjusted R&D $5B-$5.2B >REGN

4.02.2025 г., 11:37 ч. UTC

Печалби

Regeneron Pharma Sees 2025 Gross Margin on Net Product Sales 87%-88% >REGN

4.02.2025 г., 11:36 ч. UTC

Печалби

Regeneron Pharma Sees 2025 Capital Spending $850M-$975M >REGN

4.02.2025 г., 11:35 ч. UTC

Печалби

Regeneron Pharma Declares Initial Quarterly Dividend of 88c >REGN

4.02.2025 г., 11:35 ч. UTC

Печалби

Regeneron Pharma 4Q Adj EPS $12.07 >REGN

4.02.2025 г., 11:34 ч. UTC

Печалби

Regeneron Pharma 4Q U.S. Net Sales for Eylea HD, Eylea Rose 2% to $1.5B >REGN

4.02.2025 г., 11:34 ч. UTC

Печалби

Regeneron Pharma: 4Q Dupixent Global Net Sales Recorded by Sanofi Rose 15% to $3.7B >REGN

4.02.2025 г., 11:32 ч. UTC

Печалби

Regeneron Pharma Board OKs Additional $3 Billion Share Repurchase >REGN

4.02.2025 г., 11:31 ч. UTC

Печалби

Regeneron Pharma Initiates Quarterly Cash Dividend Program >REGN

31.01.2025 г., 08:30 ч. UTC

Придобивния, сливания и поглъщания

It's Bananas, but Stock Splits Can Pay Off. Here Are 5 Likely Contenders. -- Barrons.com

28.01.2025 г., 10:30 ч. UTC

Топ новини

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

31.10.2024 г., 13:58 ч. UTC

Печалби

Regeneron Takes A Ghastly Turn As High-Dose Eylea Lags And Biosimilars Loom -- IBD

31.10.2024 г., 10:52 ч. UTC

Печалби

Regeneron Earnings Top Views For Biotech Giant -- IBD

31.10.2024 г., 10:34 ч. UTC

Печалби

Regeneron Pharma 3Q Adj EPS $12.46 >REGN

31.10.2024 г., 10:33 ч. UTC

Печалби

Regeneron Pharma 3Q EPS Cut 43c by Acquired IPR&D Charge >REGN

31.10.2024 г., 10:33 ч. UTC

Печалби

Regeneron Pharma 3Q U.S. Sales for Eylea HD, Eylea Rose 3% to $1.54B >REGN

31.10.2024 г., 10:32 ч. UTC

Печалби

Regeneron Pharma: 3Q Dupixent Global Net Sales Recorded by Sanofi Rose 23% to $3.82B >REGN

31.10.2024 г., 10:30 ч. UTC

Печалби

Regeneron Pharma 3Q Rev $3.72B >REGN

31.10.2024 г., 10:30 ч. UTC

Печалби

Regeneron Pharma 3Q EPS $11.54 >REGN

31.10.2024 г., 10:30 ч. UTC

Печалби

Regeneron Pharma 3Q Net $1.34B >REGN

25.10.2024 г., 20:25 ч. UTC

Печалби

Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat -- IBD

1.08.2024 г., 11:50 ч. UTC

Печалби

Regeneron Stock Climbs After Strong Second-Quarter Performance -- IBD

1.08.2024 г., 10:37 ч. UTC

Печалби

Regeneron Pharma 2Q Adj EPS $11.56 >REGN

1.08.2024 г., 10:30 ч. UTC

Печалби

Regeneron Pharma 2Q EPS $12.41 >REGN

1.08.2024 г., 10:30 ч. UTC

Печалби

Regeneron Pharma 2Q Net $1.43B >REGN

1.08.2024 г., 10:30 ч. UTC

Печалби

Regeneron Pharma 2Q Rev $3.55B >REGN

Сравнение с други в отрасъла

Ценова промяна

Regeneron Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

47.02% нагоре

12-месечна прогноза

Среден 881.75 USD  47.02%

Висок 1,120 USD

Нисък 547 USD

Според 21 анализатори от Wall Street, предложили 12-месечна ценова цел за Regeneron Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

21 ratings

17

Купи

3

Задържане

1

Продай

Техническа оценка

By Trading Central

554.18 / 603.77Подкрепа & съпротива

Краткосрочен план

Very Strong Bullish Evidence

Средносрочен план

Weak Bullish Evidence

Дългосрочен план

Bearish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.